Pressmeddelanden, rapporter och bolagsmeddelande för Eevia Health

Eevia Health has released an investment teaser to inform shareholders and potential investors about its strategic reorientation and turnaround plan. The teaser includes information on the company's business, products, strategy, and details of a Rights Issue, available on their website. Investors should review the exemption document published on January 27, 2025. The Rights Issue timetable in 2025 includes trading and subscription periods in Sweden and Finland, with key dates from January 28 to February 17. Eevia Health, founded in 2017, produces bioactive compounds from sustainably sourced plant materials, focusing on health areas like gut and kidney health. The company operates an environmentally friendly production facility in Finland and is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA. For more details, visit their website or contact CEO Stein Ulve.

Eevia Health Plc is conducting a Rights Issue to raise approximately SEK 12.1 million, before transaction costs, with a subscription price of SEK 0.09 per share. The issue is partially underwritten by external investors. The subscription period runs from late January to mid-February 2025 in Sweden and Finland. Unused subscription rights will become invalid after the trading period. Eevia aims to restructure its business by focusing on higher-margin health products and divesting certain assets to new start-ups, Havu Health Oy and Baccus Salas Oy, in exchange for shares. These divestments are contingent on non-dilutive funding. The company plans to use the proceeds from the Rights Issue for debt repayment, working capital, and R&D investments. Eevia also seeks to negotiate better terms for its unsecured debt. The strategic shift includes focusing on gut, kidney, and urinary health solutions and expanding its market share in the global ingredient market. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden.